全文获取类型
收费全文 | 3117篇 |
免费 | 197篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 72篇 |
妇产科学 | 83篇 |
基础医学 | 435篇 |
口腔科学 | 332篇 |
临床医学 | 229篇 |
内科学 | 622篇 |
皮肤病学 | 151篇 |
神经病学 | 277篇 |
特种医学 | 82篇 |
外科学 | 343篇 |
综合类 | 17篇 |
一般理论 | 2篇 |
预防医学 | 260篇 |
眼科学 | 47篇 |
药学 | 196篇 |
中国医学 | 19篇 |
肿瘤学 | 132篇 |
出版年
2024年 | 4篇 |
2023年 | 38篇 |
2022年 | 82篇 |
2021年 | 177篇 |
2020年 | 130篇 |
2019年 | 189篇 |
2018年 | 163篇 |
2017年 | 116篇 |
2016年 | 122篇 |
2015年 | 131篇 |
2014年 | 146篇 |
2013年 | 202篇 |
2012年 | 291篇 |
2011年 | 313篇 |
2010年 | 152篇 |
2009年 | 103篇 |
2008年 | 138篇 |
2007年 | 147篇 |
2006年 | 120篇 |
2005年 | 101篇 |
2004年 | 79篇 |
2003年 | 54篇 |
2002年 | 51篇 |
2001年 | 35篇 |
2000年 | 33篇 |
1999年 | 27篇 |
1998年 | 7篇 |
1997年 | 3篇 |
1996年 | 3篇 |
1994年 | 3篇 |
1993年 | 8篇 |
1992年 | 25篇 |
1991年 | 11篇 |
1990年 | 18篇 |
1989年 | 14篇 |
1988年 | 9篇 |
1987年 | 13篇 |
1986年 | 7篇 |
1985年 | 5篇 |
1982年 | 4篇 |
1981年 | 8篇 |
1979年 | 7篇 |
1977年 | 3篇 |
1974年 | 5篇 |
1973年 | 3篇 |
1971年 | 4篇 |
1970年 | 4篇 |
1969年 | 3篇 |
1968年 | 2篇 |
1966年 | 2篇 |
排序方式: 共有3332条查询结果,搜索用时 31 毫秒
91.
92.
93.
94.
95.
Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe 下载免费PDF全文
JR Santos A Cozzi‐Lepri A Phillips S De Wit C Pedersen P Reiss A Blaxhult A Lazzarin M Sluzhynska C Orkin C Duvivier J Bogner P Gargalianos‐Kakolyris P Schmid G Hassoun I Khromova M Beniowski V Hadziosmanovic D Sedlacek R Paredes JD Lundgren 《HIV medicine》2018,19(5):324-338
Objectives
The aim of the study was to evaluate the long‐term response to antiretroviral treatment (ART) based on atazanavir/ritonavir (ATZ/r)‐, darunavir/ritonavir (DRV/r)‐, and lopinavir/ritonavir (LPV/r)‐containing regimens.Methods
Data were analysed for 5678 EuroSIDA‐enrolled patients starting a DRV/r‐, ATZ/r‐ or LPV/r‐containing regimen between 1 January 2000 and 30 June 2013. Separate analyses were performed for the following subgroups of patients: (1) ART‐naïve subjects (8%) at ritonavir‐boosted protease inhibitor (PI/r) initiation; (2) ART‐experienced individuals (44%) initiating the new PI/r with a viral load (VL) ≤500 HIV‐1 RNA copies/mL; and (3) ART‐experienced patients (48%) initiating the new PI/r with a VL >500 copies/mL. Virological failure (VF) was defined as two consecutive VL measurements >200 copies/mL ≥24 weeks after PI/r initiation. Kaplan–Meier and multivariable Cox models were used to compare risks of failure by PI/r‐based regimen. The main analysis was performed with intention‐to‐treat (ITT) ignoring treatment switches.Results
The time to VF favoured DRV/r over ATZ/r, and both were superior to LPV/r (log‐rank test; P < 0.02) in all analyses. Nevertheless, the risk of VF in ART‐naïve patients was similar regardless of the PI/r initiated after controlling for potential confounders. The risk of VF in both treatment‐experienced groups was lower for DRV/r than for ATZ/r, which, in turn, was lower than for LPV/r‐based ART.Conclusions
Although confounding by indication and calendar year cannot be completely ruled out, in ART‐experienced subjects the long‐term effectiveness of DRV/r‐containing regimens appears to be greater than that of ATZ/r and LPV/r.96.
Victor Alfonso Jimenez Diaz Antonio Tello-Montoliu Raul Moreno Ignacio Cruz Gonzalez Jose Antonio Baz Alonso Rafael Romaguera Eduardo Molina Navarro Pablo Juan Salvadores Emilio Paredes Galan Antonio De Miguel Castro Guillermo Bastos Fernandez Alberto Ortiz Saez Saleta Fernandez Barbeira Sergio Raposeiras Roubin Juan Ocampo Miguez Antonio Serra Peñaranda Mariano Valdes Chavarri Angel Cequier Fillat Andres Iñiguez Romo 《JACC: Cardiovascular Interventions》2019,12(1):22-32
Objectives
The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI.Background
Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence.Methods
This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6 different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12 reaction units (PRU) ≥208. Patients with HPR before TAVR were randomized to either aspirin + ticagrelor or aspirin + clopidogrel for 3 months. Patients without HPR continued with aspirin + clopidogrel (registry cohort). The primary endpoint was non-HPR status (PRU <208) in ≥70% of patients treated with ticagrelor at 90 days post-TAVR.Results
A total of 68 patients were included. Of these, 48 (71%) had HPR (PRU 273 ± 09) and were randomized to aspirin + ticagrelor (n = 24, PRU 277 ± 08) or continued with aspirin + clopidogrel (n = 24, PRU 269 ± 49). The remaining 20 patients (29%) without HPR (PRU 133 ± 12) were included in the registry. Overall, platelet reactivity across all the study time points after TAVR was lower in patients randomized to ticagrelor compared with those treated with clopidogrel, including those enrolled in the registry (p < 0.001). The primary endpoint was achieved in 100% of patients with ticagrelor compared with 21% with clopidogrel (p < 0.001). Interestingly, 33% of clopidogrel responder patients at baseline developed HPR status during the first month after TAVR.Conclusions
HPR to clopidogrel is present in a considerable number of patients with AS undergoing TAVR. Ticagrelor achieves a better and faster effect, providing sustained suppression of HPR to these patients. (Platelet Reactivity After TAVI: A Multicenter Pilot Study [REAC-TAVI]; NCT02224066) 相似文献97.
Alfredo Nunes Ferreira-Neto Tania Rodriguez-Gabella Leonardo Guimaraes Afonso Freitas-Ferraz Mathieu Bernier Camila Figueiredo Guimaraes Sergio Pasian Jean-Michel Paradis Robert Delarochellière Eric Dumont Siamak Mohammadi Dimitri Kalavrouziotis Mélanie Côté Philippe Pibarot Josep Rodés-Cabau 《Revista espa?ola de cardiología》2021,74(3):247-256
Introduction and objectivesWe assessed the long-term hemodynamic performance of transcatheter heart valve (THV) by paired transthoracic echocardiography (TTE), and the incidence, characteristics and factors associated with THV structural valve degeneration (SVD).MethodsA total of 212 patients who underwent transcatheter aortic valve replacement and had a potential follow-up > 5 years with at least 1 TTE ≥ 1-year postprocedure were included. All patients had a TTE at 1 to 5 years and 36 had another one at 6 to 10 years. SVD was defined as subclinical (increase > 10 mmHg in mean transvalvular gradient + decrease > 0.3 cm2 in valve area and/or new-onset mild or moderate aortic regurgitation) and clinically relevant (increase > 20 mmHg in mean transvalvular gradient + decrease > 0.6 cm2 in valve area and/or new-onset moderate-to-severe aortic regurgitation). Fifteen patients had a transesophageal echocardiography at the time of SVD diagnosis, and 85 an opportunistic computed tomography examination at 1 (0.5-2) years.ResultsTransvalvular mean gradient increased and valve area decreased over time (P < .01). At 8 years of follow-up, SVD occurred in 30.2% of patients (clinically relevant: 9.3%). Transesophageal echocardiography revealed thickened and reduced-mobility leaflets in 80% and 73% of SVD cases, respectively. No baseline or procedural factors were associated with SVD. THV underexpansion (3.5%) or eccentricity (8.2%) had no impact on valve hemodynamics/SVD at follow-up.ConclusionsA gradual THV hemodynamic deterioration occurred throughout a 10-year period, leading to SVD in ~30% of patients (clinically relevant in < 10%). Leaflet morphology/mobility were frequently impaired in SVD cases, but THV geometry did not influence valve hemodynamics or SVD. 相似文献
98.
Partially Edentulous Arches: A 5‐Year Survey of Patients Treated at the Fluminense Federal University Removable Prosthodontics Clinics in Brazil 下载免费PDF全文
99.
Paulo Roberto Santos Diego Levi Silveira Monteiro Paulo Henrique Alexandre de Paula Vicente Lopes Monte Neto Maria Leilah Ponte Monte Coelho Cecília Costa Arcanjo Sânkia Maria Lopes Aragão Camila Barbosa Gondim Janaína Teixeira Pereira Carneiro Tapeti Hyngridd Soares Mendes Luise Vasconcelos Vieira Rita de Cássia Parente Prado 《Nephrology (Carlton, Vic.)》2015,20(8):519-522
100.
Bruna Souza Felix Bravo Camila Roos Mariano Da Rocha Julien Toni De Bastos Priscila Mara Chaves e Silva 《The Journal of clinical and aesthetic dermatology》2015,8(6):30-35
The periorbital subunit is one of the first facial regions to show signs of aging, primarily due to volume depletion of the soft tissue and bony resorption. Surgical and office-based nonsurgical procedures form an important basis for periorbital rejuvenation. It is important to make a detailed clinical evaluation of the patient to indicate the most appropriate procedure to be performed. With the objective of showing a nonsurgical procedure for the rejuvenation of the periorbital area, the authors describe a technique of applying fillers in the upper and lower periorbital regions, paying attention to the anatomy of this facial region and the type of product to be used besides the expected results of the procedure and its possible adverse effects and complications. The nonsurgical rejuvenation of the periorbicular region with hyaluronic acid is a new and innovative technique. In the opinion of the authors, it is a great aesthetic impact area and consequently brings high satisfaction to patients.Maintaining a youthful and pleasant appearance of the face in today’s culture impacts quality of life in many patients. The facial contour remodeling is being revolutionized by new nonsurgical techniques.Facial aging is a complex and dynamic process. All people age differently as a result of imbalance, disharmony, and disproportion of the aging process between the overlying soft tissue and the underlying bony frameworks.1 The upper periorbital subunit is one of the first facial regions to show signs of aging, and even minor changes in its structure and volume can distort the perceived emotions and health of patients.2 An aesthetic and youthful upper periorbital subunit is characterized by a well-defined brow of appropriate height and shape, fullness of the upper periorbit, a crisp and well-defined upper eyelid crease, minimal skin excess, and good skin quality.3,4In the aging process of this facial area, one group of patients displays signs of aging due predominantly to soft tissue ptosis of the upper eyelid, requiring surgical excision. Another group presents with volume depletion of the soft tissue and bony resorption of the orbit. The loss of septal support, leading to brow prolapse and an exacerbation of upper eyelid fullness and congestion, can also contribute to the aging process. This appearance is characterized by deflation of the upper eyelid as well as hollowing and visibility of the supraorbital bony rim, leading to a sunken, hollow, and skeletonized orbit, which can make the patient appear sickly, anorexic, and old. In recent years, modern facial rejuvenation surgery has evolved toward volume restoration in addition to tissue suspension.2Comprehensive analysis of both soft tissue and bony structural changes are essential for the periorbital rejuvenation. Surgical procedures and office-based nonsurgical procedures form an important basis for periorbital rejuvenation, including cosmeceuticals, chemical peels, laser and light treatments, neurotoxins, and fillers. Improved understanding of the pathophysiology of aging and technical advancements in nonsurgical techniques has enabled us to achieve better and more comprehensive improvement for patients.5 相似文献